Publications by authors named "Yu Abe"

Claim this Profile
B
Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab.
Ukyo Kondo, Taku Kikuchi, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Yu Abe

EJHaem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.
Taku Kikuchi, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Chiaki Matsumoto, Yu Abe

Int J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
Taku Kikuchi, Miyu Watanabe, Nobuhiro Tsukada, Chiaki Matsumoto, Moe Nomura-Yogo, Yu Abe

Transpl Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?
Taku Kikuchi, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Yu Abe

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Successful management of cardiac arrest due to cytokine release syndrome following chimeric antigen receptor T-cell therapy for multiple myeloma].
Yuki Oda, Kota Sato, Kodai Kunisada, Moe Yogo, Tomomi Takei, Yu Abe

Rinsho Ketsueki· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Yu Abe

Acta Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis].
Kodai Kunisada, Mizuki Ogura, Yuki Oda, Moe Yogo, Tomomi Takei, Yu Abe

Rinsho Ketsueki· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Yu Abe

Ann Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies.
Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Yu Abe

Hematol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Yu Abe

Hematol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).
Yu Abe, Shiro Kubonishi, Masaki Ri, Masaki Iino, Kazutaka Sunami

Future Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Retrospective analysis of allogeneic hematopoietic stem cell transplantation for multiple myeloma after myeloablative conditioning with 8 Gy of total body irradiation].
Nobuhiro Tsukada, Moe Yogo, Kodai Kunisada, Yuki Oda, Tomomi Takei, Yu Abe

Rinsho Ketsueki· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of the splicing factor SART1 in the BRCA1-dependent homologous recombination repair of DNA double-strand breaks.
Kie Ozaki, Reona Kato, Takaaki Yasuhara, Yuki Uchihara, Miyako Hirakawa, Yu Abe

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Yu Abe

Int J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A retrospective analysis of 124 patients with multiple myeloma who received up-front autologous hematopoietic cell transplantation following triplet induction therapy].
Nobuhiro Tsukada, Yuki Oda, Moe Nomura, Yuki Kasuya, Tomomi Takei, Yu Abe

Rinsho Ketsueki· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Yogo, Yuki Oda, Yu Abe

Hematol Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Yu Abe

Ann Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment.
Taku Kikuchi, Nobuhiro Tsukada, Yuki Oda, Moe Nomura-Yogo, Tomomi Takei, Yu Abe

Cureus· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case Series of Patients With MYBPC1 Gene Variants Featuring Undulating Tongue Movements as Myogenic Tremor.
Saki Uneoka, Tomoko Kobayashi, Yurika Numata-Uematsu, Yoshitsugu Oikawa, Yu Katata, Yu Abe

Pediatr Neurol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma.
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].
Yuka Norihama, Moe Nomura, Yuki Oda, Yuki Kasuya, Tomomi Takei, Yu Abe

Rinsho Ketsueki· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preliminary report on retrospective dose assessment by FISH translocation assay in FDNPP Nuclear Emergency Worker Study (NEWS).
Yu Abe, Yoshio Takashima, Miho Akiyama, Naohiro Tsuyama, Kai Takebayashi

Radiat Prot Dosimetry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
Taku Kikuchi, Nobuhiro Tsukada, Moe Nomura, Yuki Kasuya, Yuki Oda, Yu Abe

Ann Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Control Method of by Co-Treatment with Protamine and Calcium Hydroxide.
Yu Abe, Michiyo Honda

Pharmaceutics· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis